ContraVir Pharmaceuticals Company Profile (NASDAQ:CTRV)

About ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals logoContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company's CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company's CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company's FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CTRV
  • CUSIP: N/A
  • Web: www.contravir.com
Capitalization:
  • Market Cap: $42.68 million
  • Outstanding Shares: 63,707,000
Average Prices:
  • 50 Day Moving Avg: $1.06
  • 200 Day Moving Avg: $1.49
  • 52 Week Range: $0.60 - $2.65
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.81
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: ($0.02) per share
  • Price / Book: -33.50
Profitability:
  • EBIDTA: ($21,360,000.00)
  • Return on Assets: -198.05%
Debt:
  • Current Ratio: 0.70%
  • Quick Ratio: 0.70%
Misc:
  • Average Volume: 1.32 million shs.
  • Beta: 2.61
  • Short Ratio: 3.51
 

Frequently Asked Questions for ContraVir Pharmaceuticals (NASDAQ:CTRV)

What is ContraVir Pharmaceuticals' stock symbol?

ContraVir Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTRV."

How were ContraVir Pharmaceuticals' earnings last quarter?

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) posted its quarterly earnings data on Friday, May, 13th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.09. View ContraVir Pharmaceuticals' Earnings History.

Where is ContraVir Pharmaceuticals' stock going? Where will ContraVir Pharmaceuticals' stock price be in 2017?

3 brokerages have issued 1 year price objectives for ContraVir Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they expect ContraVir Pharmaceuticals' share price to reach $4.00 in the next twelve months. View Analyst Ratings for ContraVir Pharmaceuticals.

Are investors shorting ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 4,954,852 shares, an increase of 41.3% from the April 28th total of 3,506,643 shares. Based on an average daily volume of 1,662,085 shares, the days-to-cover ratio is presently 3.0 days. Approximately 7.0% of the shares of the company are short sold.

Who are some of ContraVir Pharmaceuticals' key competitors?

Who owns ContraVir Pharmaceuticals stock?

ContraVir Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.22%), HighTower Advisors LLC (1.64%), Geode Capital Management LLC (0.56%), Morgan Stanley (0.44%), JPMorgan Chase & Co. (0.31%) and Prospera Financial Services Inc (0.28%). View Institutional Ownership Trends for ContraVir Pharmaceuticals.

Who sold ContraVir Pharmaceuticals stock? Who is selling ContraVir Pharmaceuticals stock?

ContraVir Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Prospera Financial Services Inc and Credit Suisse AG. View Insider Buying and Selling for ContraVir Pharmaceuticals.

Who bought ContraVir Pharmaceuticals stock? Who is buying ContraVir Pharmaceuticals stock?

ContraVir Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Geode Capital Management LLC and Morgan Stanley. View Insider Buying and Selling for ContraVir Pharmaceuticals.

How do I buy ContraVir Pharmaceuticals stock?

Shares of ContraVir Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ContraVir Pharmaceuticals stock cost?

One share of ContraVir Pharmaceuticals stock can currently be purchased for approximately $0.67.

Analyst Ratings

Consensus Ratings for ContraVir Pharmaceuticals (NASDAQ:CTRV) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (497.01% upside)

Analysts' Ratings History for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/21/2017Noble FinancialReiterated RatingBuyHighView Rating Details
4/11/2017Maxim GroupSet Price TargetBuy$4.00LowView Rating Details
6/1/2016ING GroupInitiated CoveragePositiveN/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Earnings by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Earnings History by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/13/2016Q3($0.23)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Current Year EPS Consensus Estimate: $-0.41 EPS
Next Year EPS Consensus Estimate: $-0.37 EPS

Dividends

Dividend History for ContraVir Pharmaceuticals (NASDAQ:CTRV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 5.49%
Insider Trades by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Institutional Ownership by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Insider Trades by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2016James SapirsteinCEOBuy10,000$1.00$10,000.00View SEC Filing  
11/23/2015James SapirsteinCEOBuy2,500$1.64$4,100.00View SEC Filing  
3/4/2014John P BrancaccioDirectorBuy4,393$1.49$6,545.57View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Latest Headlines for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Source:
DateHeadline
americanbankingnews.com logoZacks: Brokerages Expect ContraVir Pharmaceuticals Inc (CTRV) Will Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - May 15 at 10:00 AM
americanbankingnews.com logoContraVir Pharmaceuticals Inc (CTRV) Short Interest Update
www.americanbankingnews.com - May 10 at 7:20 AM
streetinsider.com logoContraVir Pharma (CTRV) to Advance Second-Generation Formulation of TXL for Treatment of HBV - StreetInsider.com
www.streetinsider.com - May 6 at 7:58 AM
finance.yahoo.com logoContraVir to Advance Second-Generation Formulation of Tenofovir Exalidex (TXL™) for Treatment of Hepatitis B Virus (HBV)
finance.yahoo.com - May 4 at 7:35 AM
finance.yahoo.com logoContraVir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
finance.yahoo.com - May 2 at 7:34 PM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Receives Daily Coverage Optimism Rating of -0.10
www.americanbankingnews.com - May 2 at 12:56 PM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Receiving Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 28 at 10:26 AM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Receiving Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 25 at 7:26 PM
nasdaq.com logoMid-Day Market Update: NASDAQ Hits 6,000; Heidrick & Struggles Shares Drop On Downbeat Results
www.nasdaq.com - April 25 at 4:20 PM
finance.yahoo.com logoContraVir Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
finance.yahoo.com - April 25 at 11:58 AM
finance.yahoo.com logoContraVir Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - April 24 at 4:27 PM
americanbankingnews.com logoZacks: Brokerages Expect ContraVir Pharmaceuticals Inc (CTRV) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 24 at 12:45 PM
streetinsider.com logoContraVir Pharma (CTRV) Presents Data on Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL) & CRV431
www.streetinsider.com - April 24 at 9:15 AM
americanbankingnews.com logoContraVir Pharmaceuticals Inc (CTRV) Rating Reiterated by Noble Financial
www.americanbankingnews.com - April 22 at 6:32 PM
finance.yahoo.com logoData Enhances Understanding of ContraVir’s Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL™) and CRV431
finance.yahoo.com - April 22 at 4:23 PM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Given Media Sentiment Rating of 0.41
www.americanbankingnews.com - April 21 at 2:18 PM
finance.yahoo.com logoOral Presentation at EASL Highlights ContraVir’s Tenofovir Exalidex (TXL™) Antiviral Activity in Hepatitis B (HBV) Patients
finance.yahoo.com - April 20 at 4:43 PM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Earns Daily Media Impact Rating of 0.56
www.americanbankingnews.com - April 18 at 9:35 AM
americanbankingnews.com logoMaxim Group Analysts Give ContraVir Pharmaceuticals Inc (CTRV) a $4.00 Price Target
www.americanbankingnews.com - April 17 at 10:50 AM
americanbankingnews.com logoMaxim Group Reiterates "$4.00" Price Target for ContraVir Pharmaceuticals Inc (CTRV)
www.americanbankingnews.com - April 14 at 3:34 PM
americanbankingnews.com logoContraVir Pharmaceuticals (CTRV) Earning Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 14 at 9:46 AM
finance.yahoo.com logoContraVir to Highlight New Data at EASL The International Liver Congress™ 2017 in Amsterdam, The Netherlands
finance.yahoo.com - April 11 at 1:00 PM
americanbankingnews.com logoContraVir Pharmaceuticals Inc (CTRV) Given "Buy" Rating at Noble Financial
www.americanbankingnews.com - April 8 at 8:04 AM
americanbankingnews.com logoMaxim Group Reaffirms Buy Rating for ContraVir Pharmaceuticals Inc (CTRV)
www.americanbankingnews.com - April 4 at 1:23 PM
nasdaq.com logoContraVir’s Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg)
www.nasdaq.com - April 4 at 8:49 AM
finance.yahoo.com logoCONTRAVIR PHARMACEUTICALS, INC. Financials
finance.yahoo.com - February 18 at 4:22 PM
biz.yahoo.com logoCONTRAVIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - February 14 at 8:46 PM
finance.yahoo.com logoContraVir to Highlight Clinical Data from Ongoing Phase 2a Study of Tenofovir Exalidex (TXL™) for Treating Hepatitis B
finance.yahoo.com - February 14 at 3:46 PM
prnewswire.com logoContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference - PR Newswire (press release)
www.prnewswire.com - February 7 at 10:44 PM
finance.yahoo.com logoContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 5:41 PM
bizjournals.com logoTechnical Reports on Biotech Stocks -- ContraVir Pharma, Arena Pharma, Neuralstem, and CTI BioPharma
www.bizjournals.com - January 17 at 5:25 PM
prnewswire.com logoTechnical Reports on Biotech Stocks -- ContraVir Pharma, Arena Pharma, Neuralstem, and CTI BioPharma - PR Newswire (press release)
www.prnewswire.com - January 17 at 8:39 AM
us.rd.yahoo.com logoContraVir Pharmaceuticals to Present at Biotech Showcase 2017
us.rd.yahoo.com - January 4 at 5:40 PM
streetinsider.com logoContraVir Pharma (CTRV) Awarded ~$300K Canadian Research Grant
www.streetinsider.com - January 4 at 4:14 AM
streetinsider.com logoContraVir Pharma (CTRV) Awarded ~$300K Canadian Research ... - StreetInsider.com
www.streetinsider.com - January 3 at 12:42 PM
finance.yahoo.com logoContraVir Awarded Grant from Canada's National Research Council to Advance CRV431 for the Treatment of Hepatitis B
finance.yahoo.com - January 3 at 12:42 PM

Social

Chart

ContraVir Pharmaceuticals (CTRV) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff